Abstract:OBJECTIVE:This study was designed to examine the impact of the antioxidant metallothionein (MT) on cardiac contractile, intracellular Ca(2+) function and oxidative stress in lipopolysaccharide (LPS)-treated mice.METHODS:Weight and age matched adult male FVB and cardiac-specific MT-overexpressing transgenic mice were injected intraperitoneally with 4 mg/kg Escherichia Coli LPS dissolved in sterile saline or an equivalent volume of pathogen-free saline (control groups). Six hours following LPS or saline injection, cardiac geometry and function were evaluated in anesthetized mice using the 2-D guided M-mode echocardiography. Mechanical and intracellular Ca(2+) properties were examined in hearts. Cell shortening and relengthening were assessed using the following indices: peak shortening (PS)-indicative of the amplitude a cell can shorten during contraction; maximal velocities of cell shortening and relengthening (± dl/dt)-indicative of peak ventricular contractility; time-to-PS (TPS)-indicative of systolic duration; time-to-90% relengthening (TR(90))-indicative of diastolic duration (90% rather 100% relengthening was used to avoid noisy signal at baseline concentration). The 360 nm excitation scan was repeated at the end of the protocol and qualitative changes in intracellular Ca(2+) concentration were inferred from the ratio of fura-2 fluorescence intensity (FFI) at two wavelengths (360/380). Fluorescence decay time was measured as an indicator of the intracellular Ca(2+) clearing rate. Glutathione/glutathione disulfide ratio and ROS generation were detected as the markers of oxidative stress.RESULTS:Heart rate was increased while EF was reduced in LPS-FVB mice and heart rate was reduced and EF increased in MT-LPS transgenic mice [(528 ± 72) beats/min vs (557 ± 69) beats/min, (66 ± 14)% vs (42 ± 10)%, P < 0.05]. Cardiomyocytes from the LPS treated FVB mice displayed significantly reduced peak shortening (PS) and maximal velocity of shortening/relengthening (±dl/dt) associated with prolonged time-to-90% relengthening (TR(90)), these effects were attenuated in cardiomyocytes from the MT-LPS mice [PS(5 ± 1.1)% vs (7.2 ± 0.8)%, dl/dt(160 ± 15) µm/s vs (212 ± 36) µm/s, -dl/dt (175 ± 32) µm/s vs (208 ± 29) µm/s, TR(90) (0.24 ± 0.03)s vs (0.19 ± 0.02)s, P < 0.05]. LPS treated mice showed significantly reduced peak intracellular Ca(2+) and electrically-stimulated rise in intracellular Ca(2+) as well as prolonged intracellular Ca(2+) decay rate without affecting the basal intracellular Ca(2+) levels, again, these effects were significantly attenuated in MT-LPS transgenic mice. Metallothionein overexpression also ablated oxidative stress [reduced ROS generation and increased glutathione/glutathione disulfide ratio, ROS (0.35 ± 0.08) A/µg protein vs (0.24 ± 0.03) A/µg protein]. GSH/GSSG 2.1 ± 0.2 vs 2.6 ± 0.4, P < 0.05.CONCLUSION:MT overexpression improved cardiac function and ablated oxidative stress in LPS treated mice.

Attenuation of Doxorubicin Chronic Toxicity in Metallothionein-Overexpressing Transgenic Mouse Heart.

Prior Increase in Metallothionein Levels is Required to Prevent Doxorubicin Cardiotoxicity1

Suppression of Doxorubicin Cardiotoxicity by Overexpression of Catalase in the Heart of Transgenic Mice.

Metallothionein Protects Against Doxorubicin-Induced Cardiomyopathy Through Inhibition of Superoxide Generation and Related Nitrosative Impairment

Early Transcriptional Changes in Cardiac Mitochondria During Chronic Doxorubicin Exposure and Mitigation by Dexrazoxane in Mice.

Modulation Of Cytochrome C Oxidase-Va Is Possibly Involved In Metallothionein Protection From Doxorubicin Cardiotoxicity

Inhibition of Doxorubicin Chronic Toxicity in Catalase-Overexpressing Transgenic Mouse Hearts

Metallothionein Inhibited DOX-induced Cardiac Apoptosis in Mice

Peroxiredoxins Are Involved in Metallothionein Protection from Doxorubicin Cardiotoxicity

Antioxidant Defense Against Anthracycline Cardiotoxicity by Metallothionein

Global Gene Expression Profiles of Mt Knockout and Wild-Type Mice in the Condition of Doxorubicin-Induced Cardiomyopathy

Antiapoptotic Effect and Inhibition of Ischemia/Reperfusion-Induced Myocardial Injury in Metallothionein-Overexpressing Transgenic Mice

Small-molecule mediated MuRF1 inhibition protects from doxorubicin-induced cardiac atrophy and contractile dysfunction

Metallothionein Alleviates Glutathione Depletion-Induced Oxidative Cardiomyopathy in Murine Hearts

Metallothionein-overexpressing Neonatal Mouse Cardiomyocytes Are Resistant to H2O2toxicity

Exploring the role of ferroptosis in the doxorubicin-induced chronic cardiotoxicity using a murine model

Cardiac Metallothionein Overexpression Improves Cardiac Contractile Function and Attenuates Oxidative Stress in Lipopolysaccharide-Treated Mice

Metallothionein Inhibits Ischemia-Reperfusion Injury in Mouse Heart.

Metallothionein disulfides are present in metallothionein-overexpressing transgenic mouse heart and increase under conditions of oxidative stress.

Overexpression of Thioredoxin-1 in Transgenic Mice Attenuates Adriamycin-Induced Cardiotoxicity.

The Metabolic Fingerprint of Doxorubicin-Induced Cardiotoxicity in Male CD-1 Mice Fades Away with Time While Autophagy Increases